Patent trend and competitive analysis of cancer immunotherapy in the United States
Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the United States Patent and Trademark Office in the past decade (2006–2016). A total of 2,229 patents w...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2017.1361074 |
| _version_ | 1827810019288023040 |
|---|---|
| author | Chia-Lin Pan Feng-Chi Chen |
| author_facet | Chia-Lin Pan Feng-Chi Chen |
| author_sort | Chia-Lin Pan |
| collection | DOAJ |
| description | Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the United States Patent and Trademark Office in the past decade (2006–2016). A total of 2,229 patents were identified in 13 subfields. The growth of patent number in this field has outpaced the background rate, with cytokine-related therapies, immune checkpoint inhibitors, and natural killer cell therapies growing the most rapidly. The top 15 assignees possess 27.6% (616) of the patents. Amgen is the largest patent holder, followed by Novartis, and then by Chugai Seiyaku. The top assignees have focused on different subfields, and collaborated with each other for technology development. Our competitive analysis reveals that Novartis, Chugai Seiyaku, and Abbvie lead in both patent number and average quality of patents. Meanwhile, Immunomedics owns a high-quality though relatively small patent portfolio in single-chain variable fragment technology, which is not the focus of the abovementioned forerunners. Overall, our analysis illustrates an ecosystem where industry giants and smaller-size players each occupies a niche. Selection and succession are expected to continue for years in this young ecosystem. |
| first_indexed | 2024-03-11T22:46:48Z |
| format | Article |
| id | doaj.art-595940ff752f47f0b542fc3ceba57104 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:46:48Z |
| publishDate | 2017-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-595940ff752f47f0b542fc3ceba571042023-09-22T08:17:51ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-11-0113112583259310.1080/21645515.2017.13610741361074Patent trend and competitive analysis of cancer immunotherapy in the United StatesChia-Lin Pan0Feng-Chi Chen1Institute of Population Health Sciences, National Health Research InstitutesInstitute of Population Health Sciences, National Health Research InstitutesImmunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the United States Patent and Trademark Office in the past decade (2006–2016). A total of 2,229 patents were identified in 13 subfields. The growth of patent number in this field has outpaced the background rate, with cytokine-related therapies, immune checkpoint inhibitors, and natural killer cell therapies growing the most rapidly. The top 15 assignees possess 27.6% (616) of the patents. Amgen is the largest patent holder, followed by Novartis, and then by Chugai Seiyaku. The top assignees have focused on different subfields, and collaborated with each other for technology development. Our competitive analysis reveals that Novartis, Chugai Seiyaku, and Abbvie lead in both patent number and average quality of patents. Meanwhile, Immunomedics owns a high-quality though relatively small patent portfolio in single-chain variable fragment technology, which is not the focus of the abovementioned forerunners. Overall, our analysis illustrates an ecosystem where industry giants and smaller-size players each occupies a niche. Selection and succession are expected to continue for years in this young ecosystem.http://dx.doi.org/10.1080/21645515.2017.1361074immunotherapycancerpatent landscapepatent analysiscompetitive analysis |
| spellingShingle | Chia-Lin Pan Feng-Chi Chen Patent trend and competitive analysis of cancer immunotherapy in the United States Human Vaccines & Immunotherapeutics immunotherapy cancer patent landscape patent analysis competitive analysis |
| title | Patent trend and competitive analysis of cancer immunotherapy in the United States |
| title_full | Patent trend and competitive analysis of cancer immunotherapy in the United States |
| title_fullStr | Patent trend and competitive analysis of cancer immunotherapy in the United States |
| title_full_unstemmed | Patent trend and competitive analysis of cancer immunotherapy in the United States |
| title_short | Patent trend and competitive analysis of cancer immunotherapy in the United States |
| title_sort | patent trend and competitive analysis of cancer immunotherapy in the united states |
| topic | immunotherapy cancer patent landscape patent analysis competitive analysis |
| url | http://dx.doi.org/10.1080/21645515.2017.1361074 |
| work_keys_str_mv | AT chialinpan patenttrendandcompetitiveanalysisofcancerimmunotherapyintheunitedstates AT fengchichen patenttrendandcompetitiveanalysisofcancerimmunotherapyintheunitedstates |